Daivonex Special Precautions

Effects on calcium metabolism: Due to the content of calcipotriol, hypercalcaemia may occur if the maximum weekly dose is exceeded. Serum calcium is normalised when treatment is discontinued. The risk of hypercalcaemia is minimal when the recommendations relevant to calcipotriol are followed. The maximum weekly dose in adults is 100 g of cream or ointment (equivalent to 5 mg of calcipotriol) or 60 ml of scalp solution (equivalent to 3 mg of calcipotriol). When cream, ointment or cutaneous solution are applied together, the total dose of calcipotriol should not exceed 5 mg per week.
Local adverse reactions: Daivonex ointment should not be applied to the face. The patient must be instructed in correct use of the product to avoid accidental transfer to the face and eyes. Hands must be washed after each application to avoid accidental transfer to these areas.
Daivonex ointment should be used with caution in skin folds as this may increase the risk of developing adverse reactions (see Adverse Reactions).
UV exposure: During Daivonex ointment treatment, physicians are recommended to advise patients to limit or avoid excessive exposure to either natural or artificial sunlight. Daivonex ointment should be used with UVR only if the physician and patient consider that the potential benefits outweigh the potential risks.
Due to lack of data, Daivonex ointment should be avoided in guttate, erythrodermic, exfoliative and pustular psoriasis.
Adverse reactions to excipients: Daivonex ointment contains propylene glycol as an excipient which may cause skin irritation.
Effects on the ability to drive and use machines: Daivonex ointment has no or negligible influence on the ability to drive and use machines.
Use in Children: Safety and efficacy in the treatment of children have not yet been established.